Antiobesity effects of coumestrol through expansion and activation of brown adipose tissue metabolism

Kim, Sang Nam; Ahn, Sang Yeop; Song, Hyun Doo; Kwon, Hyun Jung; Saha, Abhirup; Son, Yeonho; Cho, Yoon Keun; Jung, Young Suk; Jeong, Hyun Woo; Lee, Yun Hee

doi:10.1016/j.jnutbio.2019.108300

Cited by 24 publications

(20 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGCG (20 mg/kg/day, Sigma, St. Louis, MO, USA) dissolved in distilled water were treated for 2 weeks by oral gavage [ 17 , 18 ]. The intraperitoneal glucose tolerance test was conducted through a method described previously [ 19 ]. EGCG was detected in the plasma samples obtained from the mice treated with EGCG or vehicle controls, as described in Supplemental Methods .…”

Section: Methodsmentioning

confidence: 99%

Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues

et al. 2020

Self Cite

View full text Add to dashboard Cite

Epigallocatechin-3-gallate (EGCG) is a primary bioactive phytochemical in green tea. Its therapeutic potential in metabolic diseases has been reported; however, the molecular mechanisms of the anti-obesity effect of EGCG have not been fully elucidated. In this study, we examined the effects of EGCG on lipid metabolism and autophagy in adipose tissue. After 8 weeks of high-fat diet feeding, mice were treated with EGCG (20 mg/kg/day) for 2 weeks to test in vivo anti-obesity effects of EGCG. EGCG treatment improved glucose tolerance and caused body weight loss. Interestingly, reduced adipose tissue mass was more prominent in visceral compared to subcutaneous white adipose tissue. Mechanistically, EGCG treatment increased autophagic flux in white adipose tissue through the AMP-activated protein kinase-mediated signaling pathway. Adipocyte-specific knockout of Beclin1 mitigated the effects of EGCG on visceral adipose tissue mass and glucose tolerance, indicating that the anti-obesity effect of EGCG requires Beclin1-dependent autophagy. Collectively, our data demonstrated that EGCG has anti-obesity effects through the upregulation of Beclin1-dependent autophagy and lipid catabolism in white adipose tissue (WAT).

show abstract

Section: Methodsmentioning

confidence: 99%

Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Details of diet components are specified in the Supplementary data ( Tables S1–S3 ). Food intake monitoring was conducted by using the TSE PhenoMaster system [ 7 ], demonstrating no significant changes due to the treatment of SEE and EMIQ ( Figure S4 ).…”

Section: Methodsmentioning

confidence: 99%

“…Researchers have demonstrated that certain pharmacological or physiological conditions, such as β3-adrenergic receptor (β3-AR) agonist treatment and exposure to cold temperature remodel WAT into BAT-like phenotypes [ 6 ]. This plasticity of WAT provides a potential therapeutic target to overcome overweight and obesity by increasing energy expenditure [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Anti-Obesity Effects of Soybean Embryo Extract and Enzymatically-Modified Isoquercitrin

Kim

Cho

et al. 2020

Biomolecules

Self Cite

View full text Add to dashboard Cite

Soy isoflavones are bioactive phytoestrogens with known health benefits. Soybean embryo extract (SEE) has been consumed as a source of isoflavones, mainly daidzein, glycitein, and genistein. While previous studies have reported the anti-obesity effects of SEE, this study investigates their molecular mechanisms and the synergistic effects of co-treatment with SEE and enzymatically modified isoquercitrin (EMIQ). SEE upregulated genes involved in lipolysis and brown adipocyte markers and increased mitochondrial content in differentiated C3H10T1/2 adipocytes in vitro. Next, we use a high-fat diet-induced obesity mouse model to determine the anti-obesity effect of SEE. Two weeks of single or combined treatment with SEE and EMIQ significantly reduced body weight gain and improved glucose tolerance. Mechanistically, SEE treatment increased mitochondrial content and upregulated genes involved in lipolysis in adipose tissue through the cAMP/PKA-dependent signaling pathway. These effects required a cytosolic lipase adipose triglyceride lipase (ATGL) expression, confirmed by an adipocyte-specific ATGL knockout mouse study. Collectively, this study demonstrates that SEE exerts anti-obesity effects through the activation of adipose tissue metabolism and exhibits a synergistic effect of co-treatment with EMIQ. These results improve our understanding of the mechanisms underlying the anti-obesity effects of SEE related to adipose tissue metabolism.

show abstract

“…Similarly, a two-week treatment with coumestrol was found to reduce body weight and improved glucose tolerance in mice on an HFD due to the increased thermogenesis in BAT. On the molecular level, coumestrol was found to upregulate AMPK and sirtuin 1, and its beneficial effects were found to be inhibited by the ERα knock-out [80]. The only concern regarding these studies is that the dosage of phytoestrogens that was used in the experiments was much higher than the physiological range that was obtained from dietary intake.…”

Section: Adipose Tissue Browningmentioning

confidence: 99%

“…In turn, coumestrol was found to reduce lipid accumulation in 3T3-L1 preadipocytes via the upregulation of genes that are related to fatty acids oxidation, such as hormone-sensitive lipase, carnitine palmitoyltransferase 1, and uncoupling protein 2. Subsequently, coumestrol's administration to animals on an HFD has been found to increase lipolysis in white adipose tissue depots and, in this way, prevented obesity [80,87,88]. Additionally, formononetin was found to promote lipolysis and increase glycerol release in adipocytes [72].…”

Section: Lipogenesis and Lipolysismentioning

confidence: 99%

Targeting Abdominal Obesity and Its Complications with Dietary Phytoestrogens

2020

View full text Add to dashboard Cite

In the assessment of the health risk of an obese individual, both the amount of adipose tissue and its distribution and metabolic activity are essential. In adults, the distribution of adipose tissue differs in a gender-dependent manner and is regulated by sex steroids, especially estrogens. Estrogens affect adipocyte differentiation but are also involved in the regulation of the lipid metabolism, insulin resistance, and inflammatory activity of the adipose tissue. Their deficiency results in unfavorable changes in body composition and increases the risk of metabolic complications, which can be partially reversed by hormone replacement therapy. Therefore, the idea of the supplementation of estrogen-like compounds to counteract obesity and related complications is compelling. Phytoestrogens are natural plant-derived dietary compounds that resemble human estrogens in their chemical structure and biological activity. Supplementation with phytoestrogens may confer a range of beneficial effects. However, results of studies on the influence of phytoestrogens on body composition and prevalence of obesity are inconsistent. In this review, we present data from in vitro, animal, and human studies regarding the role of phytoestrogens in adipose tissue development and function in the context of their potential application in the prevention of visceral obesity and related complications.

show abstract

Antiobesity effects of coumestrol through expansion and activation of brown adipose tissue metabolism

Cited by 24 publications

References 27 publications

Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues

Epigallocatechin-3-Gallate Reduces Visceral Adiposity Partly through the Regulation of Beclin1-Dependent Autophagy in White Adipose Tissues

Anti-Obesity Effects of Soybean Embryo Extract and Enzymatically-Modified Isoquercitrin

Targeting Abdominal Obesity and Its Complications with Dietary Phytoestrogens

Contact Info

Product

Resources

About